Riboflavin production by roseoflavin-resistant strains of some bacteria.

Matsui, Kunihiko; Wang, Hsiu-Chuan; Hirota, Takako; Matsukawa, Hirokazu; KASAI, Sabu; Shinagawa, Kunihiro; Otani, Shuzo

doi:10.1271/bbb1961.46.2003

Cited by 10 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bacillus subtilis wild-type (strain 168) is sensitive to the antibiotic roseoflavin, however, roseoflavin resistant strains easily can be selected on solid growth media [37]. Some of these roseoflavin resistant B. subtilis strains were found to overproduce riboflavin which is an antagonist to roseoflavin [37].…”

Section: Resultsmentioning

confidence: 99%

Metabolic engineering of roseoflavin-overproducing microorganisms

2019

View full text Add to dashboard Cite

Background Roseoflavin, a promising broad-spectrum antibiotic, is naturally produced by the bacteria Streptomyces davaonensis and Streptomyces cinnabarinus . The key enzymes responsible for roseoflavin biosynthesis and the corresponding genes were recently identified. In this study we aimed to enhance roseoflavin production in S. davaonensis and to synthesize roseoflavin in the heterologous hosts Bacillus subtilis and Corynebacterium glutamicum by (over)expression of the roseoflavin biosynthesis genes. Results While expression of the roseoflavin biosynthesis genes from S. davaonensis was not observed in recombinant strains of B. subtilis , overexpression was successful in C. glutamicum and S. davaonensis . Under the culture conditions tested, a maximum of 1.6 ± 0.2 µM (ca. 0.7 mg/l) and 34.9 ± 5.2 µM (ca. 14 mg/l) roseoflavin was produced with recombinant strains of C. glutamicum and S. davaonensis , respectively. In S. davaonensis the roseoflavin yield was increased by 78%. Conclusions The results of this study provide a sound basis for the development of an economical roseoflavin production process. Electronic supplementary material The online version of this article (10.1186/s12934-019-1181-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Metabolic engineering of roseoflavin-overproducing microorganisms

2019

View full text Add to dashboard Cite

show abstract

“…Roseoflavin, a toxic riboflavin analog, is often used as an efficient chemical mutagen to induce bacterial spontaneous mutation that is accompanied with increased riboflavin production [33]. In this study, roseoflavin was used to induce the spontaneous mutation of the RYG-YYG-9049 strain, and 10 mutant strains were then randomly selected in CDM agar plates.…”

Section: Riboflavin Production Was Increased In Roseoflavin-induced Mmentioning

confidence: 99%

Screening and Spontaneous Mutation of Pickle-Derived Lactobacillus plantarum with Overproduction of Riboflavin, Related Mechanism, and Food Application

Zhang

Corke

et al. 2020

Foods

View full text Add to dashboard Cite

Riboflavin, also known as vitamin B2, plays an important role in human cell metabolism and participates in various redox reactions and in energy utilization. In this study, 90 riboflavin-producing lactic acid bacteria (LAB) were screened out from pickle juices. The yields of riboflavin in these LAB were about 0.096–0.700 mg/L, and one strain, Lactobacillus plantarum RYG-YYG-9049, was found to produce the highest riboflavin content. Next, roseoflavin was used to induce the spontaneous mutation of RYG-YYG-9049, and selected roseoflavin-resistant colonies generally produced higher riboflavin contents, ranging from 1.013 to 2.332 mg/L. The No. 10 mutant, L. plantarum RYG-YYG-9049-M10, had the highest riboflavin content. Next, the molecular mechanism of enhancing riboflavin production in RYG-YYG-9049-M10 was explored, leading to the finding that roseoflavin treatment did not change the rib operons including the ribA, ribB, ribC, ribH, and ribG genes. Unexpectedly, however, this mechanism did induce an insertion of a 1059-bp DNA fragment in the upstream regulatory region of the rib operon, as compared to the wild-type RYG-YYG-9049. To the best of our knowledge, this is the first report that roseoflavin could induce an insertion of DNA fragment in LAB to increase riboflavin content, representing a new mutation type that is induced by roseoflavin. Finally, in order to fortify riboflavin content in soymilk, RYG-YYG-9049 and RYG-YYG-9049-M10 were used to ferment soymilk, and several fermentation parameters were optimized to obtain the fermented soymilk with riboflavin contents of up to 2.920 mg/L. In general, roseoflavin induction is an economical and feasible biotechnological strategy to induce riboflavin-overproducing LAB, and this strategy can be used to develop LAB-fermented functional foods that are rich in riboflavin.

show abstract

“…Recently, it has been confirmed that several previously identified antibacterial compounds might function by targeting riboswitches, including pyrithiamine [98,99], L-aminoethylcysteine (AEC) [100], DL-4-oxalysine [101], and roseoflavin ( Figure 10) [102,103]. Pyrithiamine is an analog of thiamine.…”

Section: Riboswitchesmentioning

confidence: 95%

Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery

2011

View full text Add to dashboard Cite

Since nucleic acids (DNA and RNA) play very important roles in cells, they are molecular targets of many clinically used drugs, such as anticancer drugs and antibiotics. Because of clinical demands for treating various deadly cancers and drug-resistant strains of pathogens, there are urgent needs to develop novel therapeutic agents. Targeting nucleic acids hasn't been the mainstream of drug discovery in the past, and the lack of 3D structural information for designing and developing drug specificity is one of the main reasons. Fortunately, many important structures of nucleic acids and their protein complexes have been determined over the past decade, which provide novel platforms for future drug design and discovery. In this review, we describe some useful nucleic acid structures, particularly their interactions with the ligands and therapeutic candidates or even drugs. We summarize important information for designing novel potent drugs and for targeting nucleic acids and protein-nucleic acid complexes to treat cancers and overcome the drug-resistant problems.nucleic acid targets, DNA and RNA, protein-nucleic acid complexes, DNA duplex and junction, G-quadruplex, ribozyme, riboswitch, ribosome, topoisomerase, inhibitors, antibiotics, structure-based drug design, therapeutic agents

show abstract

Riboflavin production by roseoflavin-resistant strains of some bacteria.

Cited by 10 publications

References 0 publications

Metabolic engineering of roseoflavin-overproducing microorganisms

Metabolic engineering of roseoflavin-overproducing microorganisms

Screening and Spontaneous Mutation of Pickle-Derived Lactobacillus plantarum with Overproduction of Riboflavin, Related Mechanism, and Food Application

Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery

Contact Info

Product

Resources

About